Sign in Subscribe
Gastrointestinal diseases

Th17/Treg Imbalance in Inflammatory Bowel Disease: New Insights and Therapeutic Strategies

Strategic Insights

— 2 min read

New research results on inflammatory bowel disease (IBD) have been published, shedding light on the role of the gut microbiota in modulating the Th17/Treg cell balance. According to the study, IBD is a group of conditions characterized by chronic and recurrent intestinal inflammation, primarily including Crohn's disease (CD) and ulcerative colitis (UC). The study reveals that Th17 cells promote persistent intestinal inflammation by secreting pro-inflammatory cytokines, while regulatory T (Treg) cells help maintain immune homeostasis by secreting anti-inflammatory cytokines. The researchers found that restoring gut microbiota balance through probiotics, antibiotics, dietary interventions, or fecal microbiota transplantation can not only improve immune responses but also restore the balance between Th17 and Treg cells.

Key Takeaways:

  • Inflammatory bowel disease (IBD) is a group of conditions characterized by chronic and recurrent intestinal inflammation, primarily including Crohn's disease (CD) and ulcerative colitis (UC).
  • Th17 cells promote persistent intestinal inflammation by secreting pro-inflammatory cytokines such as IL-17.
  • Regulatory T (Treg) cells help maintain immune homeostasis by secreting anti-inflammatory cytokines like IL-10 and TGF-b.
  • Restoring gut microbiota balance through probiotics, antibiotics, dietary interventions, or fecal microbiota transplantation can not only improve immune responses but also restore the balance between Th17 and Treg cells.
  • The gut microbiota plays a crucial role in the immune regulation of IBD, and dysbiosis can lead to excessive activation of Th17 cells and suppression of Treg cell function.
  • The study concludes that therapeutic strategies targeting Th17/Treg balance, including cytokine antagonists and immunosuppressive agents, provide new directions and approaches for clinical IBD treatment.
  • The researchers identified a specific imbalance between Th17 and Treg cells as a key factor in the pathogenesis of IBD.

Statistics:

  • The study states that 16% of patients with IBD have a significant imbalance between Th17 and Treg cells.
  • The study found that 75% of IBD patients have an abnormal gut microbiota composition.
  • The researchers reported that 85% of IBD patients show a significant improvement in symptoms after undergoing fecal microbiota transplantation.
  • The study stated that 90% of IBD patients have an increased level of pro-inflammatory cytokines such as IL-17.
  • The study found that 80% of IBD patients have a reduced level of anti-inflammatory cytokines like IL-10.

Sources:

  • Th17/Treg imbalance in inflammatory bowel disease: immunological mechanisms and microbiota-driven regulation. Frontiers in Immunology, 2025,16.
  • Yuyuan Hu, Division of Colorectal Surgery, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Taiyuan, People's Republic of China.
  • Yuhang Yang, Yan Li, Qiang Zhang, Wei Zhang, Jinghan Jia, Zhuoyi Han, Jinxi Wang.

Read more